Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10

Vaccine

Volumn 28, Issue 5, 2010, Pages 1310-1317

  Da'dara, Akram A ^a   Harn, Donald A ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Helminth; HIV 1 vaccine; Multi CTL epitopes; Praziquantel; Schistosome

Indexed keywords

CONCANAVALIN A; DNA VACCINE; GAMMA INTERFERON; HIV 1C DNA VACCINE; INTERLEUKIN 10; INTERLEUKIN 4; PARASITE ANTIGEN; PRAZIQUANTEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SPLEEN CELL; SPLENOMEGALY; T LYMPHOCYTE; TIME; WORM;

AIDS VACCINES; ANIMALS; ANTHELMINTICS; CYTOKINES; FEMALE; HIV-1; MICE; MICE, INBRED BALB C; PRAZIQUANTEL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; T-LYMPHOCYTES; TIME FACTORS;

EID: 74149085067     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.019     Document Type: Article

References (58)

1. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 4599 (1983) 868-871
2. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 4648 (1984) 500-503
3. Popovic M., Sarngadharan M.G., Read E., and Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224 4648 (1984) 497-500
4. Joint United Nations Programme on HIV/AIDS. 2008 Global AIDS Epidemic. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ [Accessed, June 2009].
5. Wainberg M.A., and Jeang K.T. 25 Years of HIV-1 research-progress and perspectives. BMC Med 6 (2008) 31
6. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 455 7213 (2008) 613-619
7. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 4 (2006) 500-511
8. Graham B.S. Clinical trials of HIV vaccines. Annu Rev Med 53 (2002) 207-221
9. Ravanfar P., Mendoza N., Satyaprakash A., and Jordan B.I. HIV vaccines under study. Dermatol Ther 22 2 (2009) 158-167
10. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 27 2 (2009) 243-249
11. Corey L., McElrath M.J., and Kublin J.G. Post-step modifications for research on HIV vaccines. AIDS 23 1 (2009) 3-8
12. Chan M.S. The global burden of intestinal nematode infections-fifty years on. Parasitol Today 13 11 (1997) 438-443
13. de Silva N.R., Brooker S., Hotez P.J., Montresor A., Engels D., and Savioli L. Soil-transmitted helminth infections: updating the global picture. Trends Parasitol 19 12 (2003) 547-551
14. Utzinger J., and Keiser J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5 2 (2004) 263-285
15. van der Werf M.J., de Vlas S.J., Brooker S., Looman C.W., Nagelkerke N.J., Habbema J.D., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86 2-3 (2003) 125-139
16. Hotez P.J., Remme J.H., Buss P., Alleyne G., Morel C., and Breman J.G. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis 38 6 (2004) 871-878
17. Araujo M.I., de Jesus A.R., Bacellar O., Sabin E., Pearce E., and Carvalho E.M. Evidence of a T helper type 2 activation in human schistosomiasis. Eur J Immunol 26 6 (1996) 1399-1403
18. Grzych J.M., Pearce E., Cheever A., Caulada Z.A., Caspar P., Heiny S., et al. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J Immunol 146 4 (1991) 1322-1327
19. Pearce E.J., Kane M.C., Sun J., Taylor J.J., McKee A.S., and Cervi L. Th2 response polarization during infection with the helminth parasite Schistosoma mansoni. Immunol Rev 201 (2004) 117-126
20. Pearce E.J., Caspar P., Grzych J.M., Lewis F.A., and Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 173 1 (1991) 159-166
21. Pearce E.J., and MacDonald A.S. The immunobiology of schistosomiasis. Nat Rev Immunol 2 7 (2002) 499-511
22. Sartono E., Kruize Y.C., Partono F., Kurniawan A., Maizels R.M., and Yazdanbakhsh M. Specific T cell unresponsiveness in human filariasis: diversity in underlying mechanisms. Parasite Immunol 17 11 (1995) 587-594
23. Nutman T.B., Kumaraswami V., and Ottesen E.A. Parasite-specific anergy in human filariasis. Insights after analysis of parasite antigen-driven lymphokine production. J Clin Invest 79 5 (1987) 1516-1523
24. Semnani R.T., Law M., Kubofcik J., and Nutman T.B. Filaria-induced immune evasion: suppression by the infective stage of Brugia malayi at the earliest host-parasite interface. J Immunol 172 10 (2004) 6229-6238
25. Hewitson J.P., Grainger J.R., and Maizels R.M. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol 167 1 (2009) 1-11
26. Borkow G., and Bentwich Z. Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev 17 4 (2004) 1012-1030 [table of contents]
27. Borkow G., Leng Q., Weisman Z., Stein M., Galai N., Kalinkovich A., et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 106 8 (2000) 1053-1060
28. Zaccone P., Burton O., Miller N., Jones F.M., Dunne D.W., and Cooke A. Schistosoma mansoni egg antigens induce Treg that participate in diabetes prevention in NOD mice. Eur J Immunol 39 4 (2009) 1098-1107
29. Taylor J.J., Mohrs M., and Pearce E.J. Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J Immunol 176 10 (2006) 5839-5847
30. McKee A.S., and Pearce E.J. CD25+ CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol 173 2 (2004) 1224-1231
31. Actor J.K., Shirai M., Kullberg M.C., Buller R.M., Sher A., and Berzofsky J.A. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA 90 3 (1993) 948-952
32. Sabin E.A., Araujo M.I., Carvalho E.M., and Pearce E.J. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 173 1 (1996) 269-272
33. Cooper P.J., Chico M., Sandoval C., Espinel I., Guevara A., Levine M.M., et al. Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun 69 3 (2001) 1574-1580
34. Cooper P.J., Espinel I., Wieseman M., Paredes W., Espinel M., Guderian R.H., et al. Human onchocerciasis and tetanus vaccination: impact on the postvaccination antitetanus antibody response. Infect Immun 67 11 (1999) 5951-5957
35. Elias D., Akuffo H., Pawlowski A., Haile M., Schon T., and Britton S. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 23 11 (2005) 1326-1334
36. Elias D., Britton S., Aseffa A., Engers H., and Akuffo H. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. Vaccine 26 31 (2008) 3897-3902
37. Da'Dara A.A., Lautsch N., Dudek T., Novitsky V., Lee T.H., Essex M., et al. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Vaccine 24 24 (2006) 5211-5219
38. Sartono E., Kruize Y.C., Kurniawan A., van der Meide P.H., Partono F., Maizels R.M., et al. Elevated cellular immune responses and interferon-gamma release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis. J Infect Dis 171 6 (1995) 1683-1687
39. Takahashi H., Cohen J., Hosmalin A., Cease K.B., Houghten R., Cornette J.L., et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85 9 (1988) 3105-3109
40. Miller M.D., Yamamoto H., Hughes A.L., Watkins D.I., and Letvin N.L. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol 147 1 (1991) 320-329
41. Voss G., and Letvin N.L. Definition of human immunodeficiency virus type 1 gp120 and gp41 cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I alleles in simian-human immunodeficiency virus-infected rhesus monkeys. J Virol 70 10 (1996) 7335-7340
42. Harn D.A., Mitsuyama M., and David J.R. Schistosoma mansoni. Anti-egg monoclonal antibodies protect against cercarial challenge in vivo. J Exp Med 159 5 (1984) 1371-1387
43. Haigwood N.L., and Stamatatos L. Role of neutralizing antibodies in HIV infection. AIDS 17 Suppl. 4 (2003) S67-S71
44. Nabel G.J. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Science 308 5730 (2005) 1878-1879
45. Montefiori D.C. Neutralizing antibodies take a swipe at HIV in vivo. Nat Med 11 6 (2005) 593-594
46. Barouch D.H., Craiu A., Santra S., Egan M.A., Schmitz J.E., Kuroda M.J., et al. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 75 5 (2001) 2462-2467
47. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 9 (1994) 6103-6110
48. Novitsky V., Cao H., Rybak N., Gilbert P., McLane M.F., Gaolekwe S., et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76 20 (2002) 10155-10168
49. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 5403 (1999) 857-860
50. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 97 8 (2000) 4192-4197
51. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
52. Winstone N., Guimaraes-Walker A., Roberts J., Brown D., Loach V., Goonetilleke N., et al. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 39 4 (2009) 975-985
53. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25 11 (2007) 2120-2127
54. Letvin N.L. Progress toward an HIV vaccine. Annu Rev Med 56 (2005) 213-223
55. Elias D., Wolday D., Akuffo H., Petros B., Bronner U., and Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin Exp Immunol 123 2 (2001) 219-225
56. Thomas P.G., and Harn Jr. D.A. Immune biasing by helminth glycans. Cell Microbiol 6 1 (2004) 13-22
57. Helmy M.M., Mahmoud S.S., and Fahmy Z.H. Schistosoma mansoni: effect of dietary zinc supplement on egg granuloma in Swiss mice treated with praziqantel. Exp Parasitol (2009)
58. McElroy M.D., Elrefaei M., Jones N., Ssali F., Mugyenyi P., Barugahare B., et al. Coinfection with Schistosoma mansoni is associated with decreased HIV-specific cytolysis and increased IL-10 production. J Immunol 174 8 (2005) 5119-5123